Teva Pharmaceutical Industries Limited 0LER.IL Stock
Teva Pharmaceutical Industries Limited Price Chart
Teva Pharmaceutical Industries Limited 0LER.IL Financial and Trading Overview
Contents
Teva Pharmaceutical Industries Limited stock price | 13.23 USD |
Previous Close | 9.55 USD |
Open | 0 USD |
Bid | 8.92 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 11.25 USD |
Volume | 170 USD |
Avg. Volume | 27.37K USD |
Market Cap | 10.8B USD |
Beta (5Y Monthly) | 1.199515 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.9 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.22 USD |
0LER.IL Valuation Measures
Enterprise Value | 29.71B USD |
Trailing P/E | N/A |
Forward P/E | 3.763672 |
PEG Ratio (5 yr expected) | 1.71 |
Price/Sales (ttm) | 0.71915716 |
Price/Book (mrq) | 1.5310663 |
Enterprise Value/Revenue | 1.978 |
Enterprise Value/EBITDA | 8.003 |
Trading Information
Teva Pharmaceutical Industries Limited Stock Price History
Beta (5Y Monthly) | 1.199515 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 11.25 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 8.35 USD |
200-Day Moving Average | 8.92 USD |
0LER.IL Share Statistics
Avg. Volume (3 month) | 27.37K USD |
Avg. Daily Volume (10-Days) | 10.99K USD |
Shares Outstanding | 1.12B |
Float | 1.12B |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 49.62% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | June 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -14.87% |
Operating Margin (ttm) | 16.52% |
Gross Margin | 45.39% |
EBITDA Margin | 24.71% |
Management Effectiveness
Return on Assets (ttm) | 3.48% |
Return on Equity (ttm) | -26.58% |
Income Statement
Revenue (ttm) | 15.02B USD |
Revenue Per Share (ttm) | 13.47 USD |
Quarterly Revenue Growth (yoy) | 2.39% |
Gross Profit (ttm) | 6.97B USD |
EBITDA | 3.71B USD |
Net Income Avi to Common (ttm) | -2233999872 USD |
Diluted EPS (ttm) | -1.95 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 2.67B USD |
Total Cash Per Share (mrq) | 2.38 USD |
Total Debt (mrq) | 21.02B USD |
Total Debt/Equity (mrq) | 272.65 USD |
Current Ratio (mrq) | 1.021 |
Book Value Per Share (mrq) | 6.293 |
Cash Flow Statement
Operating Cash Flow (ttm) | 1.7B USD |
Levered Free Cash Flow (ttm) | 3.08B USD |
Profile of Teva Pharmaceutical Industries Limited
Country | United Kingdom |
State | N/A |
City | Tel Aviv |
Address | 124 Dvora Hanevi’a Street |
ZIP | 6944020 |
Phone | 972 3 914 8213 |
Website | https://www.tevapharm.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 34004 |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Q&A For Teva Pharmaceutical Industries Limited Stock
What is a current 0LER.IL stock price?
Teva Pharmaceutical Industries Limited 0LER.IL stock price today per share is 13.23 USD.
How to purchase Teva Pharmaceutical Industries Limited stock?
You can buy 0LER.IL shares on the IOB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Teva Pharmaceutical Industries Limited?
The stock symbol or ticker of Teva Pharmaceutical Industries Limited is 0LER.IL.
Which industry does the Teva Pharmaceutical Industries Limited company belong to?
The Teva Pharmaceutical Industries Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Teva Pharmaceutical Industries Limited have in circulation?
The max supply of Teva Pharmaceutical Industries Limited shares is 1.38B.
What is Teva Pharmaceutical Industries Limited Price to Earnings Ratio (PE Ratio)?
Teva Pharmaceutical Industries Limited PE Ratio is now.
What was Teva Pharmaceutical Industries Limited earnings per share over the trailing 12 months (TTM)?
Teva Pharmaceutical Industries Limited EPS is -1.9 USD over the trailing 12 months.
Which sector does the Teva Pharmaceutical Industries Limited company belong to?
The Teva Pharmaceutical Industries Limited sector is Healthcare.